Skye Bioscience (SKYE) Q4 2024 earnings summary

Executive summary

• Achieved accelerated and completed enrollment in the Phase 2a CB1 (CBeyond) trial for Nimacimab, enrolling 136 patients versus 120 planned, enabling earlier-than-expected top-line data in late Q3 or early Q4 2025.

• Extended dosing in the Phase 2a trial to 52 weeks for enhanced long-term safety and efficacy data, with interim analysis removed due to rapid enrollment.

• Secured $90 million in funding from leading life science investors, supporting clinical and manufacturing operations.

• Discontinued SBI-100 development to focus resources on Nimacimab, reflecting strategic prioritization.

• Preclinical data showed significant dose-dependent weight and fat mass loss, lean mass preservation, and improved glucose tolerance.

Financial highlights

• Research and development expenses rose to $18.7 million for 2024, up from $5.8 million in 2023, driven by clinical and manufacturing costs for Nimacimab.

• General and administrative expenses increased to $17.7 million in 2024 from $7.9 million in 2023, mainly due to stock-based compensation and professional services.

• Net loss for 2024 was $26.6 million, a decrease from $37.6 million in 2023, primarily due to a one-time $21.2 million expense for Nimacimab acquisition in 2023.

• Cash and cash equivalents stood at $68.4 million as of December 31, 2024, with an average quarterly cash burn of $6.3 million, rising to $8.1 million in Q4.

• Recognized $4.2 million gain from derecognition of contingent legal liability, $2 million insurance litigation settlement, $3 million interest income, and $1.4 million from real estate sale.

Outlook and guidance

• Top-line 26-week data from the CB1 trial expected in late Q3 or early Q4 2025; 52-week data anticipated in Q2 2026.

• Cash runway projected to fund operations through at least Q1 2027, covering completion of Phase 2a and key clinical milestones, but excluding Phase 2b/3 costs.

• Plans to initiate Phase 2b dose escalation study by Q2 2026, with regulatory engagement following top-line data.

• Additional preclinical data and market insights to be presented at scientific conferences in Q2 2025.